A detailed history of Wellington Management Group LLP transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 169,648 shares of FDMT stock, worth $3.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
169,648
Holding current value
$3.49 Million
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$17.03 - $35.87 $2.89 Million - $6.09 Million
169,648 New
169,648 $5.4 Million
Q4 2023

Feb 12, 2024

BUY
$9.76 - $21.25 $1.76 Million - $3.84 Million
180,475 New
180,475 $3.66 Million
Q3 2023

Nov 14, 2023

BUY
$12.64 - $19.76 $45,984 - $71,886
3,638 Added 2.15%
172,722 $2.2 Million
Q2 2023

Aug 14, 2023

SELL
$15.16 - $23.26 $97,509 - $149,608
-6,432 Reduced 3.66%
169,084 $3.06 Million
Q1 2023

May 12, 2023

SELL
$15.45 - $23.19 $1.32 Million - $1.98 Million
-85,188 Reduced 32.68%
175,516 $3.02 Million
Q4 2022

Feb 13, 2023

SELL
$6.85 - $25.46 $35,537 - $132,086
-5,188 Reduced 1.95%
260,704 $5.79 Million
Q3 2022

Nov 14, 2022

BUY
$6.96 - $11.48 $998,815 - $1.65 Million
143,508 Added 117.26%
265,892 $2.14 Million
Q1 2022

May 16, 2022

SELL
$13.16 - $22.64 $1.84 Million - $3.16 Million
-139,563 Reduced 53.28%
122,384 $1.85 Million
Q4 2021

Feb 11, 2022

BUY
$19.56 - $32.94 $5.12 Million - $8.63 Million
261,947 New
261,947 $5.75 Million
Q2 2021

Aug 16, 2021

SELL
$22.2 - $42.29 $2 Million - $3.82 Million
-90,251 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$35.94 - $52.67 $4.27 Million - $6.26 Million
-118,928 Reduced 56.85%
90,251 $3.91 Million
Q4 2020

Feb 12, 2021

BUY
$38.43 - $47.36 $8.04 Million - $9.91 Million
209,179 New
209,179 $8.67 Million

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $666M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.